Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1991-8-27
|
pubmed:abstractText |
The activity of MK-467, a new peripherally acting alpha 2-antagonist, was assessed in volunteers by a randomized, double-blind, crossover design. One hour after administration of either 15 mg or 30 mg MK-467 or placebo, 200 micrograms clonidine was given intravenously and observations were made for a further 8 hours. Clonidine reduced plasma norepinephrine levels to 79% +/- 7% of that of control 1 hour after infusion, an effect that was antagonized by low-dose MK-467 (p less than 0.05). Mean systolic blood pressure increased by 4 mm Hg in the first hour after the 30 mg dose of MK-467 (p less than 0.01), although there was no significant difference between the 3 study days in the maximal clonidine-induced decrease in systolic pressure, diastolic pressure, or heart rate. Clonidine induced a peak increase in mean blood glucose of 13%, which was antagonized by both doses of MK-467 (p less than 0.05). Plasma insulin was suppressed by clonidine from 72 +/- 14 to 47 +/- 7 IU.L-1, an effect antagonised by both doses of MK-467 (p less than 0.05 in each case). MK-467 had no effect on clonidine-induced increased drowsiness, xerostomia, or increase in growth hormone secretion, which is consistent with it being a peripherally acting specific alpha 2-antagonist. The small effect of MK-467 on clonidine-induced changes in plasma glucose and insulin suggests that peripheral alpha 2-adrenergic receptors play only a minor role in normal glucose homeostasis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic alpha-Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Clonidine,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/L 659066,
http://linkedlifedata.com/resource/pubmed/chemical/Norepinephrine,
http://linkedlifedata.com/resource/pubmed/chemical/Quinolizines
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0009-9236
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
50
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
71-7
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:1677320-Administration, Oral,
pubmed-meshheading:1677320-Adrenergic alpha-Antagonists,
pubmed-meshheading:1677320-Adult,
pubmed-meshheading:1677320-Blood Glucose,
pubmed-meshheading:1677320-Blood Pressure,
pubmed-meshheading:1677320-Clonidine,
pubmed-meshheading:1677320-Dose-Response Relationship, Drug,
pubmed-meshheading:1677320-Double-Blind Method,
pubmed-meshheading:1677320-Humans,
pubmed-meshheading:1677320-Insulin,
pubmed-meshheading:1677320-Male,
pubmed-meshheading:1677320-Norepinephrine,
pubmed-meshheading:1677320-Quinolizines,
pubmed-meshheading:1677320-Random Allocation,
pubmed-meshheading:1677320-Salivation
|
pubmed:year |
1991
|
pubmed:articleTitle |
Assessment of MK-467, a peripheral alpha 2-adrenergic receptor antagonist, with intravenous clonidine.
|
pubmed:affiliation |
Department of Clinical Pharmacology, RPMS, Hammersmith Hospital, London, England.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|